Page last updated: 2024-10-15

inostamycin

Description

inostamycin: inhibits cystidine 5'-diphosphate 1,2-diacyl-sn-glycerol inositol transferase; from Streptomyces; reverses drug resistance; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124081057
MeSH IDM0194960

Synonyms (9)

Synonym
nsc 638478
(2s,4s,5r)-20-de(1-hydroxypropyl)-6-demethyl-2,6-diethyl-5-hydroxy-20-(1-hydroxybutyl)lysocellin
129905-10-8
lysocellin, 20-de(1-hydroxypropyl)-6-demethyl-2,6-diethyl-5-hydroxy-20-(1-hydroxybutyl)-, (2s,4s,5r)-
inostamycin
2h-pyran-2-acetic acid, alpha,5-diethyl-6-[(1s,2s,3s,5r)-5-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyloctahydro-2'-hydroxy-5'-[(1s)-1-hydroxybutyl]-2,3',4-trimethyl[2,2'-bifuran]-5-yl]-2-hydroxy-1,3-dimethyl-4-oxoheptyl]tetrahydro-2,4-dihydroxy-3-methyl-, (alphar,2r
inostamycin a
inostamycin a (sodium salt)
AKOS040755481

Research Excerpts

Overview

Inostamycin is an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase.

ExcerptReference
"Inostamycin is an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase. "( Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line.
Baba, Y; Furukawa, S; Imoto, M; Kagata, H; Kato, Y; Koshika, S; Mochimatsu, I; Sakai, N; Tsukuda, M, 2000
)

Dosage Studied

ExcerptReference
" Treatment of Ms-1 cells with inostamycin, an inhibitor of phoshatidylinositol (PI) synthesis, reduced the dosage of paclitaxel required to induce cell death by apoptosis."( Potentiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells.
Imoto, M; Simizu, S; Takada, M; Tanabe, K; Tashiro, E; Umezawa, K, 1998
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (52.38)18.2507
2000's7 (33.33)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (19.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (80.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]